# First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors

> **NCT06622486** · PHASE1,PHASE2 · RECRUITING · sponsor: **Egle Therapeutics** · enrollment: 50 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** EGL-001

## Key facts

- **NCT ID:** NCT06622486
- **Lead sponsor:** Egle Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-27
- **Primary completion:** 2027-01-23
- **Final completion:** 2027-01-23
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06622486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06622486, "First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT06622486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*